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Subamolide B is a butanolide isolated fromCinnamomum subavenium, a medicinal plant traditionally used to treat various ailments
including carcinomatous swelling. We herein reported for the first time that subamolide B potently induced cytotoxicity against
diverse human skin cancer cell lines while sparing nonmalignant cells. Mechanistic studies on human cutaneous squamous cell
carcinoma (SCC) cell line SCC12 highlighted the involvement of apoptosis in subamolide B-induced cytotoxicity, as evidenced by
the activation of caspases-8, -9, -4, and -3, the increase in annexin V-positive population, and the partial restoration of cell viability
by cotreatment with the pan-caspase inhibitor z-VAD-fmk. Additionally, subamolide B evoked cell death pathways mediated
by FasL/Fas, mitochondria, and endoplasmic reticulum (ER) stress, as supported by subamolide B-induced FasL upregulation,
BCL-2 suppression/cytosolic release of cytochrome c, and UPR activation/CHOP upregulation, respectively. Noteworthy, ectopic
expression of c-FLIPL or dominant-negative mutant of FADD failed to impair subamolide B-induced cytotoxicity, whereas BCL-
2 overexpression or CHOP depletion greatly rescued subamolide B-stimulated cells. Collectively, these results underscored the
central role of mitochondrial and CHOP-mediated cell death pathways in subamolide B-induced cytotoxicity. Our findings further
implicate the potential of subamolide B for cutaneous SCC therapy or as a lead compound for developing novel chemotherapeutic
agents.
1. Introduction
In North America, around half of all cancers occur on
the skin [1]. In USA, nonmelanoma skin cancers, including
cutaneous squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC), have shown a doubling rate of incidence
from 1994 to 1996 and were reported to affect nearly 3.69
million patients in 2008 [2]. SCC represents the second most
common skin cancer [3]. In contrast to other nonmelanoma
skin cancers, SCC carries a significant risk of metastasis and
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accounts for the majority of the several thousand deaths
attributable to nonmelanoma skin cancer each year [4]. Expo-
sure to ultraviolet radiation (UV) is believed to be a major
etiological cofactor in the development of cutaneous SCC
[5]. Surgical treatment remains as the standard of care for
nonmelanoma skin cancers and is successful for the majority
of patients. Additionally, other traditional and new regimens
of nonsurgical approaches, including photodynamic therapy
and topical immunomodulators, provide a good cosmetic
and therapeutic success especially in those of poor surgery
candidate. Imiquimod is the most commonly used topical
drug for the treatment of actinic keratosis and superficial
BCC and SCC [6]. However, patients with aggressive or
advanced diseases frequently suffer from high rates of treat-
ment failure,morbidity, andmortality by traditionalmethods
of chemotherapy or radiotherapy. Thus, development of
novel therapeutics for effective treatment of these difficult or
aggressive cancers is in urgent demand.
Subamolide B [(3E,4R,5R)-3-tetradecylidene-4-hydroxy-
5-methoxy-5-methyl-butanolide] (Supplementary Figure 1
available online at http://dx.doi.org/10.1155/2013/630415) is
a butanolide isolated from Cinnamomum subavenium Miq.
(Lauraceae), a medium-sized evergreen tree distributed in
Burma, Cambodia, central and southern parts of China,
Indonesia, Malaysia, and Taiwan [7]. Notably, C. subavenium
has been used as a traditional Chinese medicine for treating
a broad range of illnesses, including carcinomatous swelling,
chest pain, abdominal pain, stomachache, diarrhea, hernia,
nausea, vomiting, and rheumatism [8]. Not until recently
are the bioactive butanolides of C. subavenium isolated
and functionally characterized. Subamolide A, an isomer
of subamolide B, has been reported to induce apoptosis in
human colon adenocarcinoma cell line SW480 and human
urothelial carcinoma cell line NTUB1 in addition to acting as
an inhibitor of human tyrosinase [7–9]. Furthermore, an in
vitro antimelanoma activity has been assigned to subamolide
E, another butanolide isolated fromC. subavenium [10, 11]. As
to the bioactivity of subamolide B, the only report so far is its
ability to induce apoptosis in SW480 cells [7].
The tumoricidal activity of most, if not all, chemother-
apeutics is attributed to their effect to induce cancer cell
apoptosis [12, 13]. Apoptotic signals are transmitted through
extrinsic (death receptor) or intrinsic (mitochondria) path-
ways to induce caspase activation, the cardinal hallmark
of apoptosis. Engagement of the death ligand FasL to its
cognate receptors Fas leads to cytoplasmic binding to the
death domain (DD) of the adaptor molecule Fas-associated
death domain (FADD), which in turn recruits procaspase-
8 through interaction with their death effector domains
(DEDs) to form the death-inducing signaling complex
(DISC) for caspase-8 activation [13]. Conversely, c-FLIP
competes with caspase-8 for binding to the DISC complex
but is devoid of caspase activity, thus precluding caspase-8
activation in a dominant negative manner [14]. Mitochon-
drial apoptosis pathway is controlled at the level of the
mitochondrial outer membrane integrity, which is tightly
regulated by members of BCL-2 protein family such as
prosurvival BCL-2 and BCL-xL in addition to proapoptotic
BAX and BAK [15]. In particular, a decrease in the ratio of
prosurvival to proapoptotic BCL-2 family proteins leads to
the disruption of the mitochondrial outer membrane and
consequent cytosolic release of cytochrome c to form the
apoptosome complexwithApaf-1 for caspase-9 activation [16,
17]. Activation of caspases-8 and -9 in turn initiates a series of
caspase cascade for caspase-3 activation, which accounts for
the biochemical and cellular features of apoptosis [17].
In addition tomitochondria, endoplasmic reticulum (ER)
is another organelle involved in cell death initiation [18].
Unfolded ormisfolded proteins accumulated in the ER lumen
lead to ER stress, which in turn activates the unfolded
protein response (UPR) signaling pathways consisting of
three canonical branches, namely, IRE1, PERK, and ATF6,
to induce transcriptional upregulation of chaperon proteins
like GRP78 to reestablish homeostasis in the ER [19]. Under
irremediable ER stress, the adaptive nature of theUPR signal-
ing switches to the initiation of apoptotic program, predomi-
nantly mediated by transcriptional induction of the proapop-
totic transcription factor CHOP/GADD153 (C/EBP homol-
ogous protein/Growth arrest and DNA damage-inducible
gene 153) [20, 21]. CHOP promotes cell death in part
through downregulating prosurvival BCL-2 and/or upregu-
lating proapoptotic BIM [22, 23], consequently leading to the
initiation of mitochondrial apoptosis pathway.
Although subamolide B’s proapoptotic activity on SW480
cells was shown, how subamolide B induces apoptosis was not
interrogated in that report [7]. Likewise, the cytotoxic effect
of subamolide B on skin cancer cells has never been addressed
previously. For those reasons, in this study we aimed to
elucidate the cytotoxic effect of subamolide B on human
skin cancer cell lines and also its underlying mechanism.
We herein provide evidence that subamolide B potently
induces cell death of both melanoma and nonmelanoma
skin cancer cell lines while sparing nonmalignant cells,
and subamolide B-induced cytotoxicity mainly involves the
activation of mitochondrial cell death pathway as well as
the induction of cytotoxic endoplasmic reticulum response.
Our results therefore provide a novel mechanistic insight into
the cytotoxic action of subamolide B but also implicate the
potential of using subamolide B as an antiskin cancer biologic
drug or a lead compound for developing novel anticancer
therapeutics.
2. Materials and Methods
2.1. Purification of Subamolide B from C. subavenium. The
air-dried stems ofC. subavenium (8.0 kg) were extracted with
methanol (80 L x 6) at room temperature and a methanol
extract (202.5 g) was obtained upon concentration under
reduced pressure. The methanol extract, suspended in H
2
O
(1 L), was partitioned with CHCl
3
(2 L x 5) to give fractions
soluble in CHCl
3
(123.5 g) and H
2
O (74.1 g). The CHCl
3
-
soluble fraction (123.5 g) was chromatographed over silica gel
(800 g, 70∼230mesh) using n-hexane/ethyl acetate/methanol
mixtures as eluents to produce five fractions. Part of frac-
tion 2 (9.31 g) was subjected to silica gel chromatography,
eluted with n-hexane-ethyl acetate (10 : 1), and then enriched
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gradually with ethyl acetate to furnish five fractions (2-
1∼2-5). Subsequently, fraction 2-4 (1.31 g) was subjected to
silica gel chromatography, eluted with n-hexane-ethyl acetate
(40 : 1), and enriched gradually with ethyl acetate to obtain
four fractions (2-4-1∼2-4-4). Fraction 2-4-2 (1.06 g) was
further separated using silica gel column chromatography
(eluted with n-hexane-ethyl acetate (10 : 1)) and preparative
TLC (n-hexane-ethyl acetate (30 : 1)) to give subamolide B
(42mg). The structure of subamolide B was then identified
by spectroscopic analysis (1H, 13C NMR, COSY, NOESY,
HMBC, HMQC) with purity higher than 95%.
2.2. Drugs. Purified subamolide B was stocked as 10mM in
DMSO. Thapsigargin (Calbiochem, Darmstadt, Germany)
was prepared as 1mM stock solution in DMSO. z-VAD-fmk
(N-benzyloxycarbonyl-Val-Ala-Asp-fluoro-methyl-ketone)
(Bachem, Torrance, CA, USA) was stocked in DMSO at a
concentration of 20mM. All chemicals in stock solutions
were stored in aliquots at −20∘C until use.
2.3. Cell Culture. The human cutaneous squamous cell carci-
noma cell line SCC12 (kindly provided by Prof. XiaoqiWang,
Northwestern University, USA) [24] was grown inDMEM/F-
12 (1 : 1) medium. The human malignant melanoma cell
line A375 (ATCC number: CRL-1619), human epidermoid
carcinoma cell line A-431 (ATCC number: CRL-1555), and
HEK293T cells (ATCC number: CRL-11268) were grown
in DMEM medium, whereas the human basal cell carci-
noma cell line BCC-1/KMC [25] was cultured in RPMI1640
medium. Normal human skin fibroblast cell lines CCD-
966SK (ATCC number: CRL-1881) andWS1 (ATCC number:
CRL-1502) as well as normal human lung fibroblasts IMR-
90 (ATCC number: CCL-186), MRC-5 (ATCC number:
CCL-171), and WI-38 (ATCC number: CCL-75) were all
obtained from BCRC (Bioresource Collection and Research
Center, Hsinchu, Taiwan) and grown in MEM medium. All
media were purchased from Gibco BRL (Grand Island, NY,
USA) and were supplemented with 10% heat-inactivated fetal
bovine serum (GibcoBRL,Grand Island,NY,USA), 100U/ml
penicillin, and 100mg/mL streptomycin. Cells were allowed
to grow at 37∘C in a humidified, 5% CO
2
atmosphere.
2.4. Cell Viability Determination. The effect of subamolide
B on cell viability was mostly evaluated using CellTiter
96 AQueous Non-Radioactive Cell Proliferation Assay (MTS
assay) kit (Promega, Madison, WI, USA) as previously
described [26]. Alternatively, propidium iodide (PI) exclu-
sion assay was employed to determine cell viability [27].
In brief, 4× 105 SCC12 cells were seeded onto 6-well dishes
and were subjected to 48 h treatment with subamolide B.
Cells were then trypsinized, collected by centrifugation, and
washed twice with PBS. Subsequently, cells were stained
with 10 𝜇g/ml of PI in PBS for 15min in the dark, followed
by flow cytometry analysis to determine the levels of PI
incorporation.
2.5. Colony Formation Assay. The effect of subamolide B on
the long-term survival of SCC12 cells was assessed using
colony formation assay in accordance with the reported
procedure [26]. Briefly, 5× 102 SCC12 cells treated for 24 h
with subamolide B (20𝜇M) were seeded per well of 6-well
culture dishes and were allowed to grow in drug-free media
for 10∼14 d to form colonies. The numbers of colonies were
then revealed by staining with 1% crystal violet solution in
30% ethanol. The colonies composed of 50 or more cells
were counted under microscopy. At least three independent
assays were performed to calculate the numbers of colonies
for statistical analysis.
2.6. Annexin-V/Propidium Iodide (PI) Dual Staining Assay.
Annexin V/PI dual staining assay was employed to deter-
mine the involvement of apoptosis in subamolide B-induced
cell death, using ApoTarget Annexin-V-FITC Apoptosis kit
(Biosource, Camarillo, CA, USA) as described previously
[28]. If required, the pan-caspase inhibitor z-VAD-fmk
(20𝜇M) was added to SCC12 cells 2 h before subamolide B
treatment.
2.7. Immunoblot Analysis. Immunoblottingwas performed as
previously described [26]. Antibodies against BCL-2, CHOP,
eIF2𝛼, Ser51-phosphorylated eIF2𝛼, GRP78, HA epitope,
IRE1, and PARP were all obtained from Cell Signaling
Technology (Danvers, MA, USA). The antibody detecting
Ser724- phosphorylated IRE1 was purchased from Epitomics
(Burlingame, CA, USA). Anti-𝛽-tubulin, serving as the con-
trol for equal loading, was obtained from Sigma-Aldrich (St.
Louis, MO, USA).
2.8. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNA extraction, 1st strand cDNA preparation,
and SYBR green-based real-time PCR were performed as
reported previously [26]. The sequence of primer pairs
used for semiquantitative PCR are listed as follows: FasL
forward, 5󸀠-GGTCCATGCCTCTGGAATGG-3󸀠 and FasL
reverse, 5󸀠-CACATCTGCCCAGTAGTGCA-3󸀠; Fas forward,
5󸀠-CAGAACTTGGAAGGCCTGCATC-3󸀠 and Fas reverse,
5󸀠-TCTGTTCTGCTGTGTCTTGGAC-3󸀠; CHOP forward
5󸀠-CAACTGCAGAGATGGCAGCTG-3󸀠 andCHOP reverse,
5󸀠-ACTGATGCTCCCAATTGTTCATG-3󸀠; XBP-1 forward
5󸀠-CCTTGTAGTTGAGAACCAGG-3󸀠 and XBP-1 reverse,
5󸀠-GGGGCTTGGTATATATGTGG-3󸀠; 𝛽-actin forward,
5󸀠-TCACCCACACTGTGCCCATCTACGA-3󸀠 and 𝛽-actin
reverse, 5󸀠-CAGCGGAACCGCTCATTGCCAATGG-
3󸀠. For quantitative real-time RT-PCR, the following
primer pairs were used: TRAIL forward, 5󸀠-
GACCTGCGTGCTGATCGTG-3󸀠 and TRAIL reverse,
5󸀠-TGTCCTGCATCTGCTTCAGCT-3󸀠; DR4 forward,
5󸀠-TCCACAAAGAATCAGGCAATGGAC-3󸀠 and DR4
reverse, 5󸀠-TGCAACAACAGACAATCAGCACAG-3󸀠;
DR5 forward, 5󸀠-AGTCAGAGCATCTGCTGGAAC-3󸀠
and DR5 reverse, 5󸀠-AGCACTGTCTCAGAGTCTCAG-
3󸀠; TBP (TATA-binding protein) forward, 5󸀠-CACGAA
CCACGGCACTGATT-3󸀠 and TBP reverse, 5󸀠-TTTTC
TTGCTGCCAGTCTGGAC-3󸀠. The levels of mRNA
expression of genes-in-interest were normalized to that
of TBP. Final results were presented as fold induction of
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the ratio of the genes-in-interest mRNA copy numbers to
TBP mRNA copy numbers after subamolide B stimulation
compared to that of drug-untreated control.
2.9. Luciferase Reporter Assay. The ATF6 activity reporter
plasmid p5xATF6-GL3 (Addgene plasmid 11976) carries
five ATF6 response elements in tandem to drive the
expression of firefly luciferase. The human CHOP
promoter, which encompasses the region between
−947 and +30 (+1 is the transcriptional start site) was
PCR-amplified from the genomic DNA of peripheral
blood mononuclear cells using the primer pair 5󸀠-
GGTACCGGTGAAACGTAGTCTCGCTCTG-3󸀠 (forward)
and 5󸀠-AAGCTTCAGTGCCTTAGACTTAAGTCTCTG-3󸀠
(reverse) [29, 30]. The 978-bp fragment was cloned into
the luciferase reporter plasmid pGL4.18 vector (Promega,
Madison, WI, USA) to generate the human CHOP promoter
reporter plasmid (pCHOP-Luc). Luciferase activity assay
was performed using Dual-Luciferase Reporter assay kit
(Promega, Madison, WI, USA) as reported previously [31].
Luciferase activity was normalized to Renilla luciferase
activity, and final results were expressed as fold induction
of the luciferase activity after subamolide B stimulation
compared to that of drug-untreated control.
2.10. RNA Interference. CHOP knockdown was achieved
by RNA interference-mediated suppression mechanism by
targeting the mRNA sequence 5󸀠-CAGAACCAGCAGAGG-
TCACAA-3󸀠 of the human CHOP gene (genbank accession
no. NM 004083). The complementary oligonucleotides con-
taining the target sequence were annealed and subcloned
into the pMKO retroviral vector (kindly provided by Dr.
Alan Y.-L. Lee, National Health Research Institute, Taiwan)
to generate the CHOP siRNA-expressing plasmid, shCHOP.
2.11. Construction of pBabe.puro-Based Expression Plasmids.
The BCL-2-expressing plasmid pBabe-BCL2 was generated
by subcloning the EcoRI-digested cDNA fragment con-
taining the open reading frame (ORF) of human BCL-
2 from the plasmid 3336pcDNA3 Bcl-2 (Addgene plas-
mid 8768) into the EcoRI site of pBabe-puro retrovi-
ral vector [30]. To construct the vector expressing the
dominant-negative mutant of human FADD (dnFADD), the
region containing the DD domain but devoid of the DED
domain was amplified by PCR using the primer pair 5󸀠-
ACCGGTGCCGCGCCTGGGGAAGAAGAC-3󸀠 (forward)
and 5󸀠-ATCAGGACGCTTCGGAGGTAG-3󸀠 (reverse). The
PCR-amplified fragment was then subcloned into a modi-
fied pBabe-puro vector allowing to place an upstream in-
frame HA epitope (pBabe-HA), yielding the plasmid pBabe-
HA-dnFADD. Similarly, the ORF of the long isoform of
c-FLIP (c-FLIPL) was PCR-amplified by the primers 5
󸀠-
ACCGGTTCTGCTGAAGTCATCCATCAGGTTG-3󸀠 (for-
ward) and 5󸀠-CTCGAGTTATGTGTAGGAGAGGATAAG-
TTTCTTTC-3󸀠 (reverse), followed by insertion of the PCR-
amplified fragment into the pBabe-HA vector to generate the
plasmid pBabe-HA-c-FLIPL.
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Figure 1: Cytotoxic effect of subamolide B on human skin can-
cer cell lines. (a) Dose-dependent cytotoxicity of subamolide B.
Human skin cancer cell lines, including A375 (melanoma), A-431
(epidermoid carcinoma), BCC-1/KMC (basal cell carcinoma) and
SCC12 (cutaneous squamous cell carcinoma), normal human skin
fibroblast cell lines CCD-966SK and WS1, and normal human lung
fibroblast cell lines IMR-90, MRC-5, and WI-38 were treated with
graded doses of subamolide B (0∼20 𝜇M), followed by cell viability
determination via MTS assay as described in Section 2. (b) Dose-
dependent repression of SCC12 colony formation by subamolide B.
SCC 12 cells were treated with subamolide B (0∼20𝜇M) for 24 h
and then allowed to grow in drug-free media to form colonies. 14
days later, the extent of subamolide B-mediated repression of SCC12
colony formation was evaluated by the numbers of colonies grown
on culture dishes. Shown here are the representative images from
at least three independent experiments. (c) Quantitative analysis of
subamolide B-mediated repression of SCC12 colony formation. The
numbers of colonies shown in (b) were counted and the results were
presented as the percentage of drug-treated groups compared to the
drug-free controls. ∗∗∗𝑃 < 0.001.
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Figure 2: Apoptosis is partly responsible for subamolide B-induced SCC12 cell death. ((a), (b)) Subamolide B induces dose- and time-
dependent proteolytic processing/activation of caspases-8, -9, -4, and -3. SCC12 cells were treated with subamolide B (0∼20𝜇M) for 24 h (a)
or treated with 20𝜇Mof subamolide B for indicated length of time (b), followed by immunoblot analysis of caspase activation revealed by the
status of proteolytic processing of PARP andprocaspases-8, -9, -4, and -3.𝛽-tubulinwas used as the loading control. ((c), (d)) Caspase activities
and hence apoptosis induction represent amechanismof action of subamolide B-induced SCC12 cell death. Subamolide B (20𝜇M)was used to
treat SCC12 cells for 24 h without or with cotreatment of the pan-caspase inhibitor z-VAD-fmk (20𝜇M). Cells were then revealed by Annexin-
V/Propidium iodide (PI) double staining using flow cytometry analysis. The levels of apoptotic cells were indicated as the percentage of all
cell populations as shown in (d). ∗∗∗𝑃 < 0.001.
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Figure 3: Subamolide B appears to engage the FasL/Fas cell death pathway. (a) Subamolide B upregulates FasL. SCC12 cells were treated with
0∼20𝜇M of subamolide B for 24 h, followed by immunoblotting to monitor the levels of various death receptor ligands and their cognate
receptors, including FasL/Fas and TRAIL/DR5. 𝛽-tubulin was used as the loading control. (b) Subamolide B treatment increases the mRNA
levels of FasL but not Fas. The mRNA expression levels of FasL and Fas in SCC12 cells treated with subamolide B (0∼20𝜇M) for 24 h were
monitored by semiquantitative RT-PCR analysis.𝛽-actin was used as the loading control. (c) Effects of subamolide B on themRNA expression
levels of TRAIL, DR4, and DR5. SCC12 cells treated with subamolide B as described in (b) were subjected to quantitative real-time RT-PCR
analysis for themRNA expression levels of TRAIL and the two cognate TRAIL receptorsDR4 andDR5. It is noted that subamolide B decreases
the mRNA levels of TRAIL while increasing those of DR5 and barely modulates DR4 expression.The mRNA levels are presented as the ratio
of genes-in-interestmRNA levels normalized to TATA box-binding protein (TBP) mRNA levels after subamolide B treatment to that of drug-
untreated controls. ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
2.12. pBabe.puro- and pMKO-Derived Retroviral Particle Pro-
duction and Infection. Production and infection of retroviral
vectors expressing HA-dnFADD, HA-cFLIPL, BCL-2, and
shCHOP in HEK-293T and SCC12 cells, respectively, were
conducted according to the reported protocol established in
our laboratory [31].
2.13. Statistical Analysis. All data were expressed as a
means± standard error of mean (SEM) from at least three
independent experiments. Differences between groups were
examined for statistical significance using Student’s t-test. A
𝑃 value lower than 0.05 was used as the minimum criteria for
statistical significance.
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Figure 4: Subamolide B activates the intrinsic (mitochondrial) apoptosis pathway. (a) Subamolide B dose-dependently downregulates BCL-
2. SCC12 cells treated with subamolide B (0∼20𝜇M) for 24 h were assessed for the levels of prosurvival BCL-2, BCL-xL, and proapoptotic
BAX using immunoblot analysis. 𝛽-tubulin was used as the loading control.The density of each subamolide B-treated immunoblot signal was
presented as the ratio to that of drug-untreated controls. (b) Subamolide B induces cytochrome c release to the cytosol. SCC12 cells treated
with subamolide B (0∼20 𝜇M) for 24 h were fractionated into the mitochondrial and cytosolic fractions. The levels of cytochrome c in each
fraction were then revealed by immunoblotting. The levels of COX-4 and 𝛽-tubulin were the loading controls for the mitochondrial and
cytosolic fractions, respectively. Sub-B: subamolide B.
3. Results
3.1. Subamolide B Selectively Induces Cytotoxicity in Diverse
Human Skin Cancer Cell Lines While Sparing Nonmalignant
Cells. We first evaluated the cytotoxic effect of subamolide
B on various human skin cancer cell lines, including A375
(melanoma), A-431 (epidermoid carcinoma), BCC-1/KMC
(basal cell carcinoma), and SCC12 (cutaneous squamous cell
carcinoma). As shown in Figure 1(a), subamolide Bmarkedly
reduced the viability of A375, A-431, and SCC12 cells in a
dose-dependent manner, with SCC12 cells more sensitive to
subamolide B-induced cytotoxicity (IC
50
: 9.12 𝜇M) thanA375
(IC
50
: 17.59 𝜇M) and A-431 cells (IC
50
: 13.30 𝜇M) (Table 1).
Instead, BCC-1/KMC cells were rather insensitive to sub-
amolide B-elicited cytotoxicity (IC
50
: >20𝜇M) (Figure 1(a);
Table 1). It is noteworthy that subamolide B’s cytotoxic effect
was relatively limited on all nonmalignant cell lines tested,
including human skin fibroblast cell lines CCD-966SK and
WS1 as well as human lung fibroblasts IMR-90, MRC-5, and
WI-38 (Figure 1(a); Table 1). The cytotoxic activity of sub-
amolide B was further substantiated by its ability to suppress
the colony-forming capacity of SCC12 cells (Figure 1(b)).
Particularly, treatment with 10 𝜇M and 20𝜇M of subamolide
B repressed the levels of SCC12 colony formation to 58.93 ±
2.40% and 28.20 ± 10.87% of the drug-untreated control,
respectively (𝑃 < 0.001) (Figure 1(c)). Taken together, these
results illustrated the cytotoxic effect of subamolide B on
three of the four human skin cancer cell lines examined
with limited toxicity to nonmalignant cells. Given that SCC12
cells were particularly susceptible to subamolide B-induced
cytotoxicity, this cell line was used as the cellular model
for further mechanistic inquiry on subamolide B’s cytotoxic
action.
3.2. Subamolide B-Induced Cytotoxicity Involves Caspase Acti-
vation. We next examined whether subamolide B evokes
SCC12 cell death through the induction of apoptosis. To
this end, we first asked whether subamolide B elicits caspase
activation, a cardinal hallmark of apoptosis. It is noteworthy
that subamolide B induced the cleavage of PARP, suggesting
the activation of caspases (Figure 2(a)). Detailed analyses
indicated that subamolide B treatment led to a marked
proteolytic processing of procaspases-8, -9, -4, and -3, indi-
cating that these caspases are activated. Furthermore, kinetic
study revealed a marked increase of cleaved PARP and
processed caspases-8, -9, -4, -3 at 12 h following subamolide
B treatment (Figure 2(b)). To further validate the caspase
dependence of subamolide B-induced cytotoxicity, SCC12
cells were pretreated for 2 h with the pan-caspase inhibitor
z-VAD-fmk (20𝜇M) and then were subjected to treatment
with 20𝜇M of subamolide B. It is clear to note that z-VAD-
fmk treatment suppressed the level of apoptotic cells upon
subamolide B stimulation (Figure 2(c)). Specifically, the level
of subamolide B-induced apoptotic cells was reduced from
32.55 ± 3.65% to 18.6 ± 0.42% when cotreated with z-VAD-
fmk (𝑃 < 0.001) (Figure 2(d)). Taken together, these data
established that induction of apoptosis represents one of the
modes of subamolide B’s cytotoxic action.
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Table 1: IC
50
∗ (𝜇M) of subamolide B for human cell lines examined in this study.
Skin cancer cell lines Normal skin fibroblasts Normal lung fibroblasts
A375 A-431 BCC-1 SCC12 CCD-966SK WS1 IMR-90 MRC-5 WI-38
17.59 13.30 >20 9.12 >20 >20 >20 >20 >20
∗IC50 is defined as the dosage of subamolide B capable to reduce cell viability by 50% after 48 h treatment.
3.3. Subamolide B Activates Both Extrinsic and Intrinsic Cell
Death Pathways. The proteolytic processing/activation of
caspase-8 and caspase-9 highly implicated the initiation of
the extrinsic and intrinsic apoptotic pathways, respectively.
We therefore tried to elucidate the upstream molecular
events leading to the activation of caspases-8 and -9 upon
subamolide B stimulation. The effect of subamolide B on
the expression of various death ligands and their cognate
receptors was first evaluated. Our results indicated that both
the protein and mRNA levels of FasL were clearly increased
after treatment with 20𝜇M of subamolide B, whereas the
expression of its receptor Faswas barely affected (Figures 3(a),
and 3(b)). Kinetic analysis further revealed a time-dependent
increase of FasL protein expression induced by subamolide
B (Supplementary Figure 2). Furthermore, subamolide B
downregulated TRAIL while upregulating its receptor DR5
in a dose-dependent manner (Figures 3(a) and 3(c)). Con-
versely, quantitative real-time RT-PCR analysis revealed sub-
amolide B’s limited effect on themRNA expression of another
TRAIL receptor, DR4 (Figure 3(c)). It is therefore likely
that the FasL/Fas-mediated extrinsic apoptotic pathway was
elicited by subamolide B to induce caspase-8 activation.
We next addressed how subamolide B engages the intrin-
sic (mitochondrial) apoptotic pathway to induce caspase-9
activation. Given that members of BCL-2 protein family are
primarily responsible for initiating mitochondria-mediated
apoptosis, the effect of subamolide B on the expression of
BCL-2 family proteins was examined. It is noteworthy that
subamolide B evoked a dose- and time-dependent reduction
in the level of prosurvival BCL-2, whereas it barelymodulates
the levels of prosurvival BCL-xL or the prodeath BAX (Fig-
ure 4(a); Supplementary Figure 2). This resultant alteration
of BCL-2 family protein expression apparently lowered the
ratio of prosurvival to prodeath BCL-2 family proteins, theo-
retically causing the disruption of mitochondrial membrane
integrity and consequent cytosolic release of cytochrome c
to initiate caspase-9 activation. In line with this, a dose-
dependent increase of cytochrome c levels in the cytosol was
elicited after subamolide B treatment (Figure 4(b)). Taken
together, subamolide B appears to engage the FasL-Fas axis
and lower the BCL-2/BAX ratio to activate the extrinsic and
intrinsic apoptosis pathways for the consequent activation of
caspase-8 and caspase-9, respectively.
3.4. Subamolide B Induces ER Stress Response. Activation
of caspase-4 is an indicator of a proapoptotic ER stress
response [32].Our finding that subamolide B evoked caspase-
4 activation (Figures 2(a) and 2(b)) thus implicated the
possible involvement of ER stress in subamolide B-induced
cytotoxicity. Indeed, we observed that subamolide B dose-
dependently upregulated signature ER stress markers GRP78
and CHOP (Figure 5(a)). Kinetic studies revealed a time-
dependent induction of GRP78 by subamolide B while
the induction of CHOP peaked at 12 h after subamolide B
treatment (Supplementary Figure 2). Additional evidence
indicated that subamolide B up-regulated CHOP at the level
of transcription, as supported by a dose-dependent induction
of both CHOP mRNA expression (Figure 5(b)) and the
CHOP promoter activity (𝑃 < 0.01) (Figure 5(c)) after
treatment with subamolide B. To further validate subamolide
B’s capacity to induce ER stress, we asked whether ER
stress-induced UPR signaling pathways are evoked upon
subamolide B stimulation. It is clear to note that subamolide
B treatment caused IRE1 autophosphorylation (upper panel)
and the splicing of XBP1mRNA (lower panel), indicating the
activation of the IRE1 branch of UPR signaling (Figure 5(d)).
It is also apparent that subamolide B activated the ATF6 arm
of the UPR, as revealed by a 16.09 ± 2.06 fold induction
of ATF6 transcriptional activity when treated with 10 𝜇M of
subamolide B (𝑃 < 0.001) (Figure 5(e)). Lastly, subamolide
B was found to induce PERK-mediated phosphorylation of
eIF2𝛼 to the level comparable to that induced by the ER stress
inducer thapsigargin, suggesting that subamolide B engages
the PERK branch of UPR signaling (Figure 5(f)). Altogether,
these results identified subamolide B as an inducer of ER
stress and UPR signaling.
3.5. Subamolide B-Induced Cytotoxicity Requires BCL-2 and
CHOP. Given that subamolide B activates the extrinsic,
intrinsic, and ER stress cell death pathways, we further
elucidated the functional significance of these pathways in
subamolide-induced cytotoxicity. To clarify the role of the
extrinsic cell death pathway, SCC12 cells were stably infected
with the pBabe retroviral vectors expressing HA-tagged c-
FLIPL or a dominant-negative form of FADD (dnFADD),
which preserves the DD domain for binding to the Fas
receptor but is devoid of the DED domain required for
interacting with caspase-8, in order to functionally impair
the extrinsic pathway. The established dnFADD stable clones
(Figure 6(a)) and c-FLIPL stable clones (Figure 6(b)) were
then treated with 20𝜇M of subamolide B for 48 h and
their viability was determined thereafter. To our surprise,
subamolide B effectively induced PARP cleavage and cell
death despite ectopic expression of dnFADD or c-FLIPL,
thus illustrating a dispensable role of the extrinsic cell death
pathway in subamolide B-induced cytotoxicity.
Next, SCC12 clones stably overexpressing BCL-2 were
established to evaluate the role of the intrinsic (mitochon-
drial) cell death pathway in subamolide B-induced cytotox-
icity. Consistent with previous observations, subamolide B
treatment suppressed BCL-2 levels and also led to a marked
induction of PARP cleavage and cell death in vector-infected
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Figure 5: Subamolide B is an ER stress inducer. (a) Subamolide B upregulates signature ER stress markers GRP78 and CHOP. SCC12 cells
treated with subamolide B (0∼20𝜇M) for 24 h were subjected to immunoblot analysis for the levels of GRP78 and CHOP. 𝛽-tubulin was
used as the loading control. (b) Subamolide B increases CHOP mRNA expression levels. The level of CHOP mRNA in SCC12 cells after 24 h
treatment with subamolide B (0∼20𝜇M) was assessed by semiquantitative RT-PCR analysis. 𝛽-actin was used as the loading control. (c)
Subamolide B activates the human CHOP promoter. SCC12 cells transiently transfected with the human CHOP promoter reporter plasmid
pCHOP-Luc (−947∼+30) were subjected to subamolide treatment (0∼20𝜇M) for 24 h, followed by luciferase activity assay to determine the
CHOP promoter activity. (d) Subamolide B activates the IRE1 arm of the UPR signaling pathway. SCC12 cells were treated with subamolide
B (0∼20 𝜇M) or the ER stress inducer thapsigargin (0.1𝜇M) for 24 h, followed by immunoblotting and semiquantitative RT-PCR analyses
for the levels of Ser724-phosphorylated IRE1/total IRE1 (upper panel) and the splicing of XBP1mRNA (lower panel), respectively. The levels
of 𝛽-tubulin and 𝛽-actin were the respective loading controls for immunoblotting and semiquantitative RT-PCR analyses. (e) Subamolide B
induces ATF6 activation. SCC12 cells were transiently transfected with the ATF6 transcriptional activity reporter plasmid (p5xATF6-GL3)
and then under 24 h treatment with subamolide B (0, 10𝜇M) or thapsigargin (0.1𝜇M). ATF6 transcriptional activity was then evaluated by
luciferase activity assay. (f) Subamolide B engages the PERK branch of the UPR signaling pathway. SCC12 cells after 24 h treatment with
subamolide B (0∼20𝜇M) or thapsigargin (0.1 𝜇M) were subjected to immunoblotting for the levels of PERK-mediated Ser51 phosphorylation
of eIF2𝛼 (p-eIF2𝛼) and total eIF2𝛼. 𝛽-tubulin was used as the loading control. The activity of the CHOP promoter or ATF6 is presented as
the ratio of the luciferase activities after drug treatment to that of drug-untreated controls. ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001. Sub-B: subamolide B;
TG: thapsigargin.
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control cells (Figure 6(c)). In contrast, enforced BCL-2
expression markedly reduced the extents of PARP cleavage
and cell death elicited by subamolide B (Figure 6(c)). These
data therefore supported the involvement of the intrinsic cell
death pathway in subamolide B-induced cytotoxicity.
CHOP is regarded as a principal proapoptotic transcrip-
tional factor mediating cytotoxic ER stress responses [20, 21]
and, notably, was up-regulated by subamolide B (Figures
5(a)–5(c)). We therefore addressed the role of ER stress
cell death pathway by evaluating subamolide B’s cytotoxic
effect on SCC12 cells whose endogenous CHOP was depleted
by its specific shRNA (shCHOP). It is noteworthy that
CHOP depletion significantly repressed PARP cleavage and
also enhanced the survival of subamolide B-treated cells
(Figure 6(d)). Collectively, the evidence that both BCL-2 and
CHOP are required for subamolide B-induced cytotoxicity
supports the notion that both the mitochondrial and ER
stress-mediated cell death represent two fundamental modes
of action underlying the cytotoxic effect of subamolide B.
4. Discussion
Natural products isolated from plants or medicinal herbs
have been invaluable resources of antineoplastic agents or
lead compounds for new drug development [33–35]. Sub-
amolide B is a butanolide isolated from a medicinal plant
Cinnamomum subavenium traditionally used for treating
multiple ailments, including carcinomatous swelling [8]. In
this study, the cytotoxic effect and the underlyingmechanism
of subamolide B were examined. We herein present evidence
that subamolide B as a single agent shows effective in vitro
cytotoxicity against skin cancer cell lines A375 (melanoma),
A-431 (epidermoid carcinoma), and SCC12 (cutaneous SCC)
while sparing nonmalignant cells (Figure 1). Using SCC12
cell line as our cellular model, we further demonstrated that
subamolide B induces activation of caspases-8, -9, -4, and -3
(Figure 2) and stimulates the cell death pathwaysmediated by
FasL/Fas (Figure 3), mitochondria (Figure 4), and ER stress
(Figure 5). Notably, functional blockade analysis further
elucidates that it is the activation of mitochondrial pathway
and cytotoxic ER stress response but not FasL/Fas pathway
that is required for subamolide B to induce SCC12 cell death
(Figure 6). Based upon these findings, the mechanism of
subamolide B’s cytotoxic action is delineated (Figure 7). To
our best knowledge, this is the first report as to subamolide
B-induced cytotoxicity and the underlying mechanism on
human cutaneous SCC cells.
Induction of apoptosis is well recognized as the pri-
mary cytotoxic mechanism for the antitumor effect of most
chemotherapeutic agents [12, 13]. In line with this, we identi-
fied the involvement of apoptosis in subamolide B-induced
cell death. This notion is supported by our observation
that subamolide B treatment led to the activation of both
initiator caspases-8/-9 and effector caspase-3, in addition to
the ER stress-associated caspase-4 (Figures 2(a) and 2(b)).
Importantly, caspase dependence in subamolide B-induced
cytotoxicity was further substantiated by a marked rescue of
SCC12 cell viability from subamolide Bwhen the pan-caspase
inhibitor z-VAD-fmk was cotreated (Figures 2(c) and 2(d)).
On the other hand, it is interesting to note that z-VAD-
fmk impaired but failed to abolish subamolide B-induced
cell death (Figures 2(c) and 2(d)). These findings therefore
illustrate that apoptosis induction is only partly responsible
for the cytotoxic mechanism of subamolide B and further
implicate that other modes of cell death are involved in
subamolide B-elicited cytotoxicity, whose identities need to
be elucidated in the future.
It is noteworthy that most chemotherapeutic agents
eradicate cancer cells through initiation of mitochondrial
apoptosis pathway [36]. The present study revealed that
subamolide B induces the activation of cell death pathways
mediated by FasL/Fas, mitochondria, and ER stress, as
evidenced by FasL upregulation (Figure 3), BCL-2 down-
regulation/cytosolic release of cytochrome c (Figure 4), and
activation of UPR signaling/CHOP transcriptional upregu-
lation (Figure 5), respectively. However, FasL/Fas pathway
was proved dispensable for subamolide-induced cytotoxicity,
because enforced expression of dnFADD or c-FLIPL failed
to rescue SCC12 cells from subamolide B treatment (Fig-
ures 6(a) and 6(b)). Conversely, BCL-2 overexpression (Fig-
ure 6(c)) or CHOP depletion (Figure 6(d)) greatly enhanced
the survival of subamolide B-treated cells, thus underscoring
the involvement of mitochondria- and ER stress-mediated
cell death pathways in the cytotoxic mechanism of sub-
amolide B. Importantly, CHOP-elicited cell death is known
to involve suppression of prosurvival BCL-2 [22] and/or
induction of prodeath BIM [23] culminating in the initiation
of mitochondrial cell death pathway [20, 21, 37]. In this
context, the modes of cytotoxic action of subamolide B
are consistent with those of most current chemotherapeutic
agents, which induce cancer cell death predominantly by
triggering the mitochondrial pathway while amplifying cell
death signal outputs through the extrinsic pathway [36].
Moreover, it is interesting tomention that ER stress-mediated
cell death only partly relies on caspase activities [38], thus
ostensibly accounting for the partial caspase dependence
of subamolide B-induced cytotoxicity (Figures 2(c) and
2(d)).
Data presented here implicates subamolide B as a poten-
tial agent for cutaneous SCC therapy. It is noted that
imiquimod is currently the most commonly used topical
drug for the treatment of superficial BCC and SCC [6].
Intriguingly, we found that SCC12 cells were relatively refrac-
tory to imiquimod-induced cytotoxicity, as evidenced by our
observation that imiquimod as high as 50 𝜇g/ml reduced
SCC12 cell viability only to 65.00 ± 4.32% of the drug-
untreated control after 24 h treatment (Supplementary Figure
3). In contrast, subamolide B treatment for 24 h showed an
IC
50
of 6.897𝜇g/ml (20.27𝜇M) (Supplementary Figure 3) and
thus ismuchmore effective than imiquimod to induce in vitro
cytotoxicity against SCC12 cells. Still, it should be noted that it
remains inconclusive as to whether subamolide B is generally
a more potent anticutaneous SCC agent than imiquimod,
because we were unable to evaluate the cytotoxicity of
subamolide B and imiquimod on additional cutaneous SCC
cell lines due to their limited availability. Future studies in
preclinical models are therefore necessary to substantiate the
potential of subamolide B for cutaneous SCC therapy.
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Figure 6: Subamolide B induces SCC12 cell death mainly through activating mitochondrial cell death pathway and cytotoxic ER stress
response. ((a), (b)) The FasL/Fas cell death pathway is not required for subamolide B-induced cytotoxicity. SCC12 cells were stably infected
with the pBabe vector alone or the vectors expressing a dominant-negative form of FADD (dnFADD) (a) or c-FLIPL (b) to block the function
of the FasL/Fas cell death pathway. These stable clones were then treated with 20 𝜇M of subamolide B for 24 h to monitor the status of PARP
cleavage in addition to enforced expression of dnFADD or c-FLIPL (left panel), or for 48 h to determine cell viability using PI exclusion assay
(right panel). (c) Mitochondrial cell death pathway is involved in subamolide B-induced cytotoxicity. SCC12 cells stably carrying the pBabe
vector alone or the vector overexpressing BCL-2 to impair the activation of mitochondrial cell death pathway were treated with subamolide
B (20𝜇M) for 24 h and 48 h to evaluate the effect of enforced BCL-2 expression on subamolide B-induced PARP cleavage (left panel) and
cytotoxicity (right panel), respectively. (d) Involvement ofCHOP-mediated ER stress cell death pathway in subamolide B-induced cytotoxicity.
SCC12 cells were stably infected with the pMKO vector alone or the vector expressing CHOP-specific siRNA (shCHOP) to inhibit ER stress-
induced cell death. These stable clones were then treated with subamolide B (20𝜇M) for 24 h and 48 h to evaluate the effect of CHOP
knockdown on subamolide B-induced PARP cleavage (left panel) and cytotoxicity (right panel), respectively. ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
Sub-B: subamolide B.
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Figure 7: A proposedmodel for the cytotoxicmechanisms of action
of subamolide B. Subamolide B activates the cell death pathways
mediated by FasL/Fas, mitochondria, and ER stress, as evidenced
by FasL upregulation, BCL-2 downregulation/cytosolic release of
cytochrome c, and induction of the UPR signaling pathway/CHOP
upregulation, respectively. These cell death pathways lead to the
activation of caspase-8, caspase-9, caspase-4, and caspase-3. Caspase
activity and thus apoptosis are partially responsible for the cytotoxic
activity of subamolide B, as cotreatment with the pan-caspase
inhibitor z-VAD-fmk impairs but not abolishes subamolide B-
induced cell death. FasL/Fas-mediated pathway appears dispensable
for subamolide B’s cytotoxic activity, since blockade of this pathway
by c-FLIPL or the dominant-negative mutant of FADD (dnFADD)
barely affects subamolide B-induced cell death. Conversely, BCL-2
overexpression or CHOP knockdown markedly enhances the sur-
vival of subamolide B-treated cells, confirming the requirement of
mitochondrial and ER stress cell death pathways for subamolide B-
induced cytotoxicity. Whether CHOP contributes to subamolide B’s
cytotoxic action through suppression of BCL-2 and/or upregulation
of BIM requires further validation.
5. Conclusion
We provide clear evidence in this study to demonstrate
subamolide B-elicited potent cytotoxic effect on various skin
cancer cell lines with limited cytotoxicity to nonmalignant
cells. Mechanistic investigation in SCC12 cells further defines
the activation of mitochondrial cell death pathway and the
induction of cytotoxic ER stress response as the funda-
mental modes of action underlying subamolide B-induced
cytotoxicity. These findings unveil mechanistic insights into
the cytotoxic action of subamolide B but also implicate the
potential of subamolide B as an anticutaneous SCC agent or
as a lead compound to develop novel therapeutic agents for
cancers including cutaneous SCC.
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